Why IMU is a multi multi bagger, page-11774

@RussianRoolet quoted yesterday

IMU does not have a PER today nor in any foreseeable year or even decade.

The current MC is $1B which is about $1B overvalued by any real measure.

Put IMU in the same bucket as crypto with no intrinsic value and no long term future other than continued dillution of shares via CR after CR..

Ideally I don’t like to call people out but having spent some time writing an article last week (published yesterday) wherein I explained the ability of immunotherapy company’s such as Seagen (e.g., with Tidvak in 2021) to gain fast track FDA approval and move toward commercialisation and revenue in real time, sometimes you have to sound out misinformation. As noted yesterday it is is my belief Imugene (IMU-ASX) shall obtain fast track FDA approval for Her Vaxx and either CF33 or Vaxinia (or both) in either 2025 or 2026, due to the reasons outlined in my aforementioned Sunday post. In other words in the foreseeable future. The chances of Imugene taking a decade to achieve revenue as this poster insinuates, if not suggests (see above), is simply too far fetched to comprehend. Her Vaxx was invented years and years ago and has already surpassed Phase 1 and 2 clinical trials with outstanding OSR results. Like CF33 and Vaxinia, Her Vaxx, with an exceptional safety profile and strong signs and efficacy, is set to commence the push toward fast track FDA approval in late 2024. A move that is therefore eminently achievable in the near term.

Our erstwhile poster (see above) draws our attention to the lack of a PER ratio for Imugene (IMU-ASX), as other protagonists do when commenting on Imugene, as if that is a reason to quash the stocks market cap. PER is an abbreviation for Price to Earnings Ratio by the way, commonly referred to as P/E ratio, a tool utilised by some to calculate the value of shares on a stock exchange. Please keep in mind this is but one of many tools utilised by economists, stock brokers and indeed analysts to assess the intrinsic value of a stock. As I have long encouraged the Board of Imugene to participate in a NASDAQ listing I would draw the abovementioned poster, and whilst doing so other aparachies on these threads to a NASDAQ listed stock entitled REATA Pharmaceuticals (see herein).


The FDA approval covers the use of the company’s SKYCLARYS as a treatment for patients suffering from Friedreich’s ataxia. Patients will note that this is the first time the FDA has approved a drug to treat this rare disease.

"Friedreich’s ataxia is an “ultra-rare, inherited neurodegenerative disorder that is typically diagnosed during adolescence. ”

REATA Pharmaceuticals is a prime example of just how out of touch local analysts, the ASX 200 and many posters herein are with the value of biotech stocks worldwide, not too mention Imugene (IMU - ASX). In short REATA Pharmaceuticals does not have a PER Ratio (see above). It like Imugene currently has no revenue. Yet last week, having obtained FDA Approval for a drug that treats a potential market size of only about 5,000 patients in the U.S., the stock rose to $90 per share, or a market cap of $3.34 Billion USD (see chart). Thats’s right folks, Friedreich’s ataxia the disease REATA Pharmaceuticals obtained FDA Approval to treat is extremely rare, unlike solid tumours, the disease treated by Imugene’s Vaxinia. The American Cancer Society informs us that in 2021 the estimated numbers of new cancer cases will be an estimated 1.9 million. Therefore Imugene’s Vaxinia alone has the potential to treat close to 400 times more patients than REATA Pharmaceuticals.Yet Imugene is despite it’s massive pipeline of game changing products is valued at practically one sixth of the value of REATA Pharmaceuticals today.

Estimated numbers of new cancer cases and deaths in 2021 (In 2021, there will be an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States.)

Cancer Facts & Figures 2021 is an educational companion for Cancer Statistics 2021, a scientific paper published in the American Cancer Society journal, CA: A Cancer Journal for Clinicians. The Facts & Figures annual report

I myself am bouyed by the great news REATA Pharmaceuticals delivered to the NASDAQ last week, and more importantly excited for the long standing sufferers of the rare disease Friedreich’s ataxia. But realistically one can understand how exuberant Imugene CEO and Managing Director Leslie Chong and innovator Saul Priceman M.D. are about the prospect of Imugene’s Ocarlytics platform obtaining FDA Approval to treat human patients in 2023. Why on these figures (IMU - ASX) could be potentially worth over $100 USD per share, based on a comparison with the REATA Pharmaceuticals share price alone. That said I am in no way suggesting this level of uplift in the IMU - ASX share price shall eventuate. But can I suggest that those commenting with very little market knowledge, or more importantly those spreading misinformation about Imugene’s market capitalisation, and the company’s lack of revenue, should cease. And that analogy I might add speaks to leading financial journalists in this country as well, who like posters on this thread, local stockbrokers and many investors on the ASX 200 alike, have no idea how to value pre revenue biotech stocks, such as REATA Pharmaceuticals or Imugene on world markets.

DYOR - Seek investment advice as and when required - Opinions Only